Matt Hoffman, Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He executive produces the NeurologyLive Mind Moments® podcast, and hosted the Medical World News show Deep Dive. Follow him on Twitter @byMattHoffman or email him at [email protected]
Among a large cohort of outpatient and inpatient individuals, the risk of Alzheimer disease, Parkinson disease, ischemic stroke, and intracerebral hemorrhage were all elevated after infection, with stroke risk increased compared with other respiratory infections.
The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.
The trial was terminated because of the expectation of enrollment not being feasible, driven by the recent CMS national coverage determination. The phase 4 confirmatory ENVISION trial is still ongoing.
Bradford C. Sippy, the chief executive officer of Tremeau Pharmaceuticals, spoke about the company’s work to reformulate rofecoxib, known now as TRM-201, to treat acute migraine.
After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.
The pharmacodynamic and pharmacokinetic effects of the novel Amneal Pharmaceuticals therapy suggest that it can overcome the current absorption and exposure limitations of the oral levodopa therapies used to treat those with Parkinson disease motor fluctuations.
In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.
Data from a PMD Alliance survey of more than 700 individuals with PD or their care partners showed significant associations between decreased social support and exasperation of nonmotor and cognitive symptoms of PD.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.
A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.
In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.
In a first, but indirect, comparison of the 3 available formulations of amantadine for the treatment of Parkinson disease, only the delayed-release/extended-release formulation (Gocovri) resulted in improvements in both in OFF time and dyskinesia.
Members who voted no expressed that they would have liked to have seen results from an additional randomized controlled trial.
The investigators noted that the data on tolerability and efficacy support that treatment with opicapone among older adults with PD requires no age-related dose adjustments.
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Afsara Zaheed; Richard Bogan, MD, FCCP, FAASM; and Ruth Benca, MD, PhD. [LISTEN TIME: 18 minutes]
The digital tool was used to evaluate more than 12,500 recorded upper body movements among a cohort of 41 adults undergoing poststroke rehabilitation exercises.
The oral tablet formulation of rofecoxib has been shown to reach maximum plasma concentrations at 2 hours post dose compared with 3 for the historical formulation, which the company believes can improve the time to onset of action.
A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.
After previously being approved for use in the stroke and acquired brain injury populations, the Ekso Bionics product now becomes the first such device approved in the multiple sclerosis patient population.
Robert Fox, MD, who presented the DISCO-MS study results at the CMSC 2022 Annual Meeting, offered his closing thoughts on the data and the take-home messaging for clinicians.
Data from a cohort of almost 5000 women seen at Montefiore Health System emergency departments suggest that primary headache, likely migraine, is underdiagnosed, and a high proportion of these women being of Black and Hispanic backgrounds.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.
Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.
Robert Fox, MD, offered perspective on data from the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis and how it compares with day-to-day clinical practice.
Headache frequency remained the top driver of higher disability scores, but opposing to prior findings, school versus summer was not a significant predictor of disability, suggesting that pandemic schooling changes affected coping abilities to cause less disability.
Robert Fox, MD, shared the details of the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis, presented at the CMSC 2022 Annual Meeting.
The director of the Montefiore Headache Center spoke about the Migraine Clinical Outcome Assessment System project and the need for better patient-reported outcome measures in migraine clinical care.
Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.
A retrospective review of more than 1000 electronic medical records suggests that for those with migraine, the presence of neck pain, anxiety, depression, and insomnia show no comparative differences in treatment response predictability.
